Objective Recent reports have revealed that corticosteroid (PSL) therapy has a long-term beneficial effect for stabilization of renal function in progressive IgA nephropathy.
Introduction
Since IgA nephropathy was first reported in 1968 by Berger et al, it is nowrecognized as one of the most common types of primary glomerulonephritis worldwide (1) . There is accumulating evidence that 20-50% of cases with IgA nephropathy develop end-stage renal failure within the 20 years (2) (3) (4) . However, no adequate therapeutic strategies have been reported.
Kobayashi et al (5) recently reported that corticosteroid (PSL)
therapy has a long-term beneficial effect for stabilization of renal function in progressive IgA nephropathy with massive proteinuria of 1.0 g/day or more, whenpatients have a preserved renal function with creatinine (Cr) clearance of 70 ml/ min or more, although the effectiveness of PSLtherapy in IgA nephropathy is controversial. In our institute, PSL therapy has been performed for treatment of IgA nephropathy since 1985 and we feel that acute reduction of serum creatinine during the period of PSL treatment maybe useful to predict further stabilization of renal function after PSLtherapy. In this study, we analyzed the short-term response in both renal function and daily proteinuria to PSL therapy in patients with IgA nephropathy and investigated whether any clinicopathological parameters were correlated with the response to PSL.
Patients and Methods
Weretrospectively analyzed changes in renal function, daily proteinuria and routine blood chemistry during a short-term course of PSL therapy in patients with IgA nephropathy. Twenty-eight patients with PSLtherapy were included in this study; patients were diagnosed as having primary IgA nephropathy at the Internal Medicine Department of Saga Medical School between 1985 and 1995. As an index of renal function, we used the percentage of changes in serum Cr per year (%ACrmg/dl/year) and Cr clearance. Daily proteinuria, if not available, was calculated by protein/Cr ratio in a single urine sample as previously described (6) (7) (8) . Routine examination included determination of blood pressure, serum total protein (TP), albumin (Alb), blood urea nitrogen (BUN), serum Cr, uric acid (UA), total cholesterol (T.cho) and serum IgA. Data were collected every month from prior to treatment to the end of PSLtherapy. In addition, the cases were divided into two groups according to changes in renal function evaluated by %ACrmg/dl/year in the period of PSL treatment: group I, improved renal function (-10% or less); group II, no significant changes in renal function (-9% or more).
Renal histological examination Pathological examination was performed by analysis of 8 routine sections stained with hematoxylin-eosin, periodic acidSchiff and periodic acid-Schiff methenamine silver. The histological grading (G) and staging (S) for IgA nephropathy described by Shigematsu (9) were used. Briefly, in each biopsy specimen, glomerular (g) and tubulointerstitial (int) lesions were evaluated semiquantitatively. The glomerular lesions were divided into two components: endocapillary change (en) and extracapillary change (ex). In the evalution of each component, acute and chronic changes were separately estimated. The grade (G) expressed the extent of acute lesions and the stage (S) expressed the extent of chronic lesions. The extent of each glomerular grading (G) and staging (S) was evaluated in every glomerulus, and the final Gen, Gex, Sen, and Sex values were expressed as sums of numbers divided by the total number of glomeruli. Tubulointerstitial grading (Gint) and staging (Sint) were also estimated. The extent of each histological injury was semiquantitatively graded from 0 to 3. Thus, the total histological grade (G) was obtained by the sum of Gen, Gex and Gint, and the total histological stage (S) was the sum of Sen, Sex and Sint. Segmental glomerular necrosis (SGN) was defined as a segmental lesion of the destructive capillary tuft often associated with fibrin deposition within and around the capillaries. To allow comparison of the histological parameters between the groups, we calculated the percentages of the cases with mesangial proliferation of 2+ or more, C/F crescents and/ or SGN,glomerular sclerosis of 20%or more, tubulointerstitial damageof 1+or moreand arteriolosclerosis of 1+or more. Cases with C/F crescents and/or SGNin one glomerulus or more were considered positive. Meannumber of glomeruli examined per case in group I (12.5±2.1) was almost equivalent to that in group II (12.8±2.1).
Sta tistical analysis
Wilcoxon's signed-rank test was used for statistical analysis of changes in clinical data (mean values±SD) including renal function in all 28 cases and in each group, whereas MannWhiteney U test was used for comparison of clinical data between the groups. In addition, chi-square test was used for comparison of frequency of hypertension, angiotensin converting enzyme inhibitor (ACE-I) and cyclophosphamide (CY) administration, and histological parameters. A level of p<0.05 was accepted as statistically significant.
Results

Clinical characteristics
of the 28 cases (Table 1) : The twentyeight cases consisted of 21 males and 7 females with a mean age of 35±14 years old. PSL was started at an initial dose of60 mg/day in 25 cases, 40 mg/day in 2 cases and 20 mg/day in 1 case, and then gradually tapered. Mean duration of PSL administration was 15±9 months. The observation period before PSL therapy varied in each patient ranging from 3 months to 91 months (13±22 months). Daily proteinuria was more than 1.0 g/day in 24 cases, of which 6 showed nephrotic-range proteinuria. The remaining 4 cases showed mild proteinuria of less than 1.0 g/day. Twenty-two cases showed mild elevation of serum Cr ranging from 0.95 mg/dl to 1.99 mg/dl. The values of serum IgA were more than 350 mg/dl in 12 cases. Nine cases were complicated with hypertension. ACE-I and CYwas used in 9 and 6 cases, respectively. Changes in renal function, daily proteinuria and clinical (Table 3) : Groups I and II consisted of 15 and 13 cases, respectively. The clinical parameters were not significantly different between the groups except for TP. There were no significant differences in the frequency of hypertension, or ACE-I and CYadministration between the groups. Changes in serum Cr in each group (Fig. 1) : In group I, serum Cr was acutely and significantly decreased by 3 months of PSLtherapy and remained low until the end of the treatment period. In contrast, group II showed no significant changes in serum Cr levels during therapy. Changes in daily proteinuria in each group (Fig. 2) : In group I, reduction of daily proteinuria reached a peak after 3 months of PSL therapy and remained low throughout the treatment period. On the other hand, although daily proteinuria was transiently decreased after 3 months of the therapy in group II, no significant reduction was observed at the end of the treatment period.
Comparison of morphological indices between the groups (Table 4) : C/F crescents and/or SGNoccurred with a significantly higher incidence in group I (87%) than in group II (46%) (p<0.05). In contrast, no significant differences were observed in mesangial proliferation, glomerular sclerosis, tubulointerstitial damage or arteriolosclerosis between the groups. Similarly, score of the histological G was significantly higher in group I than in group II (p<0.05), whereas the score of the histological S did not differ between the groups.
Discussion
In this study, we showedthat corticosteroid therapy is effective at least during the period of PSLtreatment in patients at the end of therapy). with progressive IgA nephropathy presenting mildly deteriorating renal function. Early studies of steroid therapy in IgA nephropathy showedno beneficial effects on the clinical courses in progressive patients with nephrotic syndromeand moderate to severe histology (10, ll) . In contrast, recent studies showed favorable clinical course of progressive IgA nephropathy with steroid therapy (5, 12, 13) . Goumenos et al (13) reported that 66 treated patients whoshowed heavier proteinuria and more severe histopathological involvement had significantly more favorable clinical courses for a meanfollow-up period of 46 months as compared to 48 untreated patients. The treatment consisted of oral prednisolone (40 mg/day) and azathioprine (2 mg/day), which was gradually tapered over a median duration of 24 months. Similarly, Kobayashi et al (5) reported that cases with IgA nephropathy treated with corticosteroid had significantly morestable renal function than those without corticosteroid treatment over a 10-year follow-up period, when the cases showed proteinuia of 1.0-2.0 g/day and a preserved creatinine crearance rate of 70 ml/minor moreas initial values. Kobayashi et al (5) suggested that failure of stabilization of renal function in the early studies might have been due to the short duration of PSL treatment in IgA nephropathy as prednisolone was administered for only 3 or 4 months. These observations suggested that renal function may be stabilized by steroid therapy with a duration of 12 months or more in cases with progressing IgA nephropathy, although the maintenance dose is unknown. This study showeda more favorable response to PSLtherapy in cases with than in those without C/F crescents and/or SGN during the course of PSLtherapy. In our previous study using 100 serial sections of 128 cases with IgA nephropathy, SGNas well as C/F crescents occurred more frequently than suggested previously and we suggested that repeated occurrence of the lesions mayparticipate in slowly progressive deterioration of renal function (15) . In this regard, IgA nephropathy may be considered slowly progressive crescentic glomerulonephritis. It is reasonable to stabilize renal function by PSL therapy in progressive IgA nephropathy, because in crescentic glomerulonephritis PSL therapy with immunosuppressive agents is knownto ameliorate rapidly progressive deterioration of renal function. In addition, this study showed that PSL therapy decreased urinary protein excretion associated with an ameliorating effect on renal function. Wepreviously observed that the severity of daily proteinuria tended to be correlated with the occurrence of crescents and SGN,associated with a beneficial effect of PSL therapy on proteinuria and renal function, in 8 cases of IgA nephropathy with nephrotic-range proteinuria (16) . These findings suggested that the stabilization of renal function and reduction of daily proteinuria maybe at least in part associated with reduction of crescent and SGNformation in IgA nephropathy treated with PSL therapy, although it re-mains unknownwhether any histological lesions are suppressed by PSL therapy.
In conclusion, the present study suggested that PSLtherapy is effective at least during the course of treatment in stabilization of renal function accompaning a reduction of proteinuria in progressive IgA nephropathy especially presenting the formation of C/F crescents and/or SGN,and that the early response to PSLin reducing serum Cr and proteinuria after around 3 months of the therapy may be clinically useful to predict the prognosis of IgA nephropathy. Further studies are needed to clarify the duration and dose of PSL required to maintain stabilization of renal function in progressive IgA nephropathy.
